[go: up one dir, main page]

PT2329848E - Lixisenatida como terapia de extensão à insulina glargina e à metformina para tratar a diabetes do tipo - Google Patents

Lixisenatida como terapia de extensão à insulina glargina e à metformina para tratar a diabetes do tipo

Info

Publication number
PT2329848E
PT2329848E PT91758771T PT09175877T PT2329848E PT 2329848 E PT2329848 E PT 2329848E PT 91758771 T PT91758771 T PT 91758771T PT 09175877 T PT09175877 T PT 09175877T PT 2329848 E PT2329848 E PT 2329848E
Authority
PT
Portugal
Prior art keywords
lixisenatide
metformin
diabetes
therapy
add
Prior art date
Application number
PT91758771T
Other languages
English (en)
Inventor
Louise Silvestre
Elisabeth Souhami
Xiaodan Wei
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41800749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2329848(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PT2329848E publication Critical patent/PT2329848E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT91758771T 2009-11-13 2009-11-13 Lixisenatida como terapia de extensão à insulina glargina e à metformina para tratar a diabetes do tipo PT2329848E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09175877.1A EP2329848B2 (en) 2009-11-13 2009-11-13 Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes

Publications (1)

Publication Number Publication Date
PT2329848E true PT2329848E (pt) 2013-01-23

Family

ID=41800749

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91758771T PT2329848E (pt) 2009-11-13 2009-11-13 Lixisenatida como terapia de extensão à insulina glargina e à metformina para tratar a diabetes do tipo

Country Status (11)

Country Link
EP (1) EP2329848B2 (pt)
CY (1) CY1113755T1 (pt)
DK (1) DK2329848T4 (pt)
ES (1) ES2398012T5 (pt)
HR (1) HRP20121029T4 (pt)
ME (1) ME01546B (pt)
PL (1) PL2329848T5 (pt)
PT (1) PT2329848E (pt)
RS (1) RS52629B2 (pt)
SI (1) SI2329848T2 (pt)
SM (1) SMT201300013B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2349324T3 (pl) 2008-10-17 2018-02-28 Sanofi-Aventis Deutschland Gmbh Kombinacja insuliny i agonisty GLP-1
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
PT3417871T (pt) 2009-11-13 2021-02-15 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
US20130085102A1 (en) * 2011-02-02 2013-04-04 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MY170713A (en) * 2011-10-28 2019-08-27 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2
BR112015024659A8 (pt) 2013-04-03 2019-12-17 Sanofi Sa formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação
DK3010530T3 (en) * 2013-06-17 2019-04-15 Sanofi Aventis Deutschland FIXED-FORMULATED FORMULATION BETWEEN INSULIN GLARGIN AND LIXISENATIDE
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels

Also Published As

Publication number Publication date
SI2329848T1 (sl) 2013-02-28
HRP20121029T4 (hr) 2019-10-18
SMT201300013B (it) 2013-03-08
ME01546B (me) 2014-04-20
RS52629B (en) 2013-06-28
HRP20121029T1 (hr) 2013-01-31
EP2329848B2 (en) 2019-06-19
ES2398012T3 (es) 2013-03-13
ES2398012T5 (es) 2020-02-26
EP2329848B1 (en) 2012-10-24
PL2329848T3 (pl) 2013-05-31
SI2329848T2 (sl) 2019-10-30
PL2329848T5 (pl) 2019-12-31
DK2329848T3 (da) 2013-02-04
EP2329848A1 (en) 2011-06-08
CY1113755T1 (el) 2016-07-27
RS52629B2 (sr) 2019-11-29
DK2329848T4 (da) 2019-09-09

Similar Documents

Publication Publication Date Title
HRP20121029T1 (hr) Liksisenatid kao pomoä†na terapija uz inzulin glargin i metformin kod lijeäśenja dijabetesa tip 2
PL2324853T3 (pl) Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
HRP20170209T1 (hr) Liksisenatid kao dodatna terapija uz bazalni inzulin kod dijabetesa tipa 2
IL219945A (en) 1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
IL209887A0 (en) Treatment for diabetes in patients inappropriate for metformin therapy
IL250549B (en) Acetyl analogs of insulin that are resistant to protease and their use for the preparation of a drug for the treatment and prevention of diabetes
IL212903A0 (en) Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
HK1164112A1 (en) Treating hyperglycemia with glp-1 glp-1
SI2707017T1 (sl) Liksisenatid in metformin za zdravljenje sladkorne bolezni tipa 2
LT2611458T (lt) Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
PT2459207E (pt) Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
ZA201105094B (en) Combination of insulin with triazine derivatives and its use for treating diabetes
GB0919603D0 (en) Use of thymosin beta-4 for treatment of type II diabetes
ZA201008998B (en) Treatment for diabetes in patients inappropriate for metformin therapy
EG27140A (en) Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
ZA200909123B (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
GB0912906D0 (en) Treatment of diabetes and metabolic syndrome
GB0910904D0 (en) Treatment of diabetes and metabolic syndrome
GB0904271D0 (en) Treatment of diabetes and metabolic syndrome